LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Chiusa

3.31 -0.6

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.24

Massimo

3.33

Metriche Chiave

By Trading Economics

Entrata

44M

-26M

Vendite

-5.8M

42M

Margine di Profitto

-61.388

Dipendenti

550

EBITDA

44M

-22M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+21.43% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

206M

1.3B

Apertura precedente

3.91

Chiusura precedente

3.31

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 dic 2025, 15:21 UTC

Utili

Correction to Home Depot Outlook Headline on Dec. 9

23 dic 2025, 23:54 UTC

Discorsi di Mercato

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 dic 2025, 23:40 UTC

Discorsi di Mercato

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 dic 2025, 21:21 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 dic 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara to Hold Deposit in Escrow

23 dic 2025, 21:20 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 dic 2025, 21:19 UTC

Acquisizioni, Fusioni, Takeovers

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 dic 2025, 21:13 UTC

Acquisizioni, Fusioni, Takeovers

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 dic 2025, 20:16 UTC

Discorsi di Mercato

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 dic 2025, 20:14 UTC

Discorsi di Mercato

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 dic 2025, 19:13 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 dic 2025, 18:58 UTC

Discorsi di Mercato

Gold Has Another Record-Setting Day -- Market Talk

23 dic 2025, 18:32 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 dic 2025, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

23 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

23 dic 2025, 17:09 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 dic 2025, 16:21 UTC

Discorsi di Mercato

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 dic 2025, 16:16 UTC

Discorsi di Mercato

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 dic 2025, 16:15 UTC

Discorsi di Mercato

Precious Metals Pare Gains -- Market Talk

23 dic 2025, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Bank: Closing Expected Around Mid-January

23 dic 2025, 16:03 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 dic 2025, 16:02 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 dic 2025, 16:01 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Bank Receives Green Light for Acquisition in Poland

23 dic 2025, 15:42 UTC

Acquisizioni, Fusioni, Takeovers

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 dic 2025, 15:42 UTC

Acquisizioni, Fusioni, Takeovers

Telefonica Doesn't Set Out Financial Details of Divestment

23 dic 2025, 15:41 UTC

Acquisizioni, Fusioni, Takeovers

Telefonica: Deal Will Allow Focus on Core Markets

23 dic 2025, 15:40 UTC

Acquisizioni, Fusioni, Takeovers

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 dic 2025, 15:19 UTC

Discorsi di Mercato

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Confronto tra pari

Modifica del prezzo

Maravai LifeSciences Holdings Inc (Class A) Previsione

Obiettivo di Prezzo

By TipRanks

21.43% in crescita

Previsioni per 12 mesi

Media 4.25 USD  21.43%

Alto 4.5 USD

Basso 4 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Maravai LifeSciences Holdings Inc (Class A) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.02 / 2.115Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat